Grifols stock: buy or sell?

GRFS stock price: $21.69 0.18% At close on November 15th, 2019

Updated on:
November 15th, 2019

4

Shares of Grifols remained constant a tight 0.18% and closed at $21.69.

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally.

Should I buy Grifols stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Grifols stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean GRFS will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Grifols stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we collected 2 ratings published for GRFS stock in the last 30 days.

Is GRFS a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-6-27JPMorgan Chase & Co.NeutralOverweight
2019-2-8Berenberg BankBuyHold

Grifols stock analysis

Daily outlook

Grifols remained constant a tight 0.18% and closed at $21.69.

Grifols remained steady a tight 0.18% and closed at $21.69. On October/3 GRFS price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. Since SMA100d and SMA200d crossed up on July, GRFS price slid a -0.91%.

GRFS stock chart (daily)

Weekly outlook

Shares of Grifols closed this week at $21.69 and stepped up a slightly good 0.79%.

Having descending tops is not good news for the long side. Although it's only a warning signal, investors should be on alert during next weeks to identify possible new signals. You should be expectant to Grifols price to not slide under , as this would complicate possible price recovery in the short and mid-term. Since SMA20d and SMA40w crossed up early July, GRFS price climbed $0.02 per share (0.09%). Since price and SMA40w lines crossed up by mid June, GRFS climbed $2.68 (14.10%).

GRFS stock chart (weekly)

Grifols stock price history

Grifols stock went public on June 2nd, 2011 with a price of $6.551. Since then, GRFS stock surged a 231.10%, with a yearly average of 28.90%. If you had invested right after GRFS's IPO a $1,000 in Grifols stock in 2011, it would worth $2,311.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Grifols stock historical price chart

GRFS stock reached 52-week highs on August at $23.03, and all-time highs 2018-06-13 with a price of 24.47.

Grifols stock price target is $22.50

How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. Currently, only 1 price forecast for Grifols stock was published in the last month:
GRFS stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-6-27JPMorgan Chase & Co.Upgrades$21.00$22.507.1%
(in average)$21.00$22.507.0%

Financials and fundamental analysis

Earnings date and Earnings per Share

After posting its last earnings report on April, Grifols . As soon as we get its actual EPS from the earnings report, we will extend this report.
GRFS earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/an/an/a
2017-Q2-n/an/an/a
2017-Q3-n/an/an/a
2017-Q42018-02-280.310.28-9.7%
2018-Q12018-05-030.280.293.6%
2018-Q22018-07-270.340.340.0%
2018-Q32019-01-03n/an/an/a
2018-Q42019-04-03n/an/an/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to 2017, last anual revenues report draw a beatiful gain of 3.91% to $4,486.72 M USD. When comparing 2018 vs 2017, on the other hand, profit margin (that is, the net income divided by revenues) depreciated a -2.05% to 13.30%.

GRFS annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$2,740 M-$346 M12.6%-
2014$3,355 M22.46%$470 M14.0%36.09%
2015$3,935 M17.26%$532 M13.5%13.16%
2016$4,050 M2.93%$545 M13.5%2.50%
2017$4,318 M6.62%$663 M15.3%21.49%
2018$4,487 M3.91%$597 M13.3%-9.97%

Quarterly financial results

Grifols reported $1,222.81 million in revenues for 2018-Q4, a 6.91% improvement compared to previous quarter. Reported quarter income marked $128.35 million with a profit margin of 10.50%. Profit margin slightly fell a -2.56% compared to previous quarter when profit margin was 13.05%. When comparing sales to same quarter last year, Grifols sales marked a dazzling growth and skyrocketed a 14.51%. Looking back to recent quarterly results, Grifols posted 3 positive quarters in a row.
GRFS quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$1,131 M-$143 M12.6%-
2017-Q2$1,292 M14.20%$164 M12.7%15.12%
2017-Q3$1,060 M-17.95%$154 M14.5%-6.37%
2017-Q4$1,068 M0.74%$231 M21.6%50.06%
2018-Q1$1,023 M-4.20%$143 M14.0%-37.90%
2018-Q2$1,097 M7.24%$176 M16.0%22.43%
2018-Q3$1,144 M4.26%$149 M13.1%-14.95%
2018-Q4$1,223 M6.91%$128 M10.5%-14.05%

Grifols ownership

When you are planning to buy shares of a stock, it's always worth to overview its ownership structure.

Grifols shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.00% of all shares.

In case of Grifols stock, 60.84% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for GRFS stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related companies:

GRFSAMGNBAXCBPOJNJ
Market cap$14.8 B$131.2 B$41.6 B$4.5 B$354.9 B
Total shares684.1 M594.2 M510.6 M38.3 M2,630.0 M
Float shares1,100.0 M592.9 M509.7 M16.4 M2,630.0 M
  - Institutional holdings (%)60.8%81.9%88.2%47.3%69.2%
  - Insider holdings (%)0.0%0.2%0.1%44.1%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Grifols summary

Friday, November 15th, 2019
Open$21.65
Close$21.69
Day range$21.63 - $21.77
Previous close$21.65
Session gain0.18%
Average true range$0.36
50d mov avg$20.74
100d mov avg$21.26
200d mov avg$20.09
Daily patternlt01a
Weekly pattern lt01a

Grifols performance

To better understand Grifols performance you must becnhmark its gains with other related stocks in same sector or industry. For Grifols, the comparison is made against Amgen, Baxter International, China Biologic Products, , Kimberly-Clark and Mylan.
Stock3m6m12m
GRFSGrifols-1.36%19.31%4.08%
AMGNAmgen8.98%31.78%17.20%
BAXBaxter Internatio...-6.12%7.77%23.77%
CBPOChina Biologic Pr...18.43%25.67%57.15%
JNJ3.50%-1.24%-5.02%
KMBKimberly-Clark-5.78%3.64%22.24%
MYLMylan-4.48%-9.88%-49.31%

Grifols competitors

We selected a few stocks to conform a list of Grifols competitors to watch if you are interested in investing in GRFS: